New CAR-T therapy offers hope for leukemia patients too sick for chemo
NCT ID NCT07335094
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of CAR-T cell therapy (with a protein called TLR2) in 60 adults newly diagnosed with B-cell acute lymphoblastic leukemia or lymphoma who cannot tolerate intensive chemotherapy. Participants receive a single infusion of these engineered immune cells after a mild chemotherapy prep. The study focuses on safety and how well the cancer responds, with follow-up over three years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- humanized CD19 CAR-T cells with TLR2
- What this could lead to
- If it works, this could offer a gentler, effective treatment option for adults with B-cell leukemia/lymphoma who are too frail for standard intensive chemotherapy.
- What could go wrong
- This is a very early (Phase 1) trial with only 60 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and neurological side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.